Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? (Q36175746)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

review article

1 reference

title

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

M Colozza

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

E Azambuja

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

C Sotiriou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

D Larsimont

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

M J Piccart

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

publication date

24 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

1723-1739

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15980158%20AND%20SRC:MED&resulttype=core&format=json

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

13 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic value of proliferation in invasive breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

In VitroLabeling of Solid Tissues with Tritiated Thymidine for Autoradiographic Detection of S-Phase Nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Consensus report of the task force on standardisation of DNA flow cytometry in clinical pathology. DNA Flow Cytometry Task Force of the European Society for Analytical Cellular Pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Improved DNA flow cytometric, DNA ploidy, and S‐phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Proliferative activity in primary breast carcinomas is a salient prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic markers in node-negative breast cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1,301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project (MMMCP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

S-phase fraction and nuclear size in long term prognosis of patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Can thymidine kinase levels in breast tumors predict disease recurrence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Multiparametric Prognostic Evaluation of Biological Factors in Primary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Mammalian deoxyribonucleoside kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The Ki-67 protein: from the known and the unknown

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Ki67 protein: the immaculate deception?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

MIB-1 proliferative activity in invasive breast cancer measured by image analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

MIB-1 labelling index is an independent prognostic marker in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Preoperative systemic treatment: prediction of responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin E2, the cycle continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin E and survival in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin D1 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cyclin D1 and prognosis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Inhibitors of mammalian G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

TGFbeta signaling in growth control, cancer, and heritable disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

p27 deregulation in breast cancer: prognostic significance and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Prognostic role of p27Kip1 and apoptosis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Correlation of p27 protein expression with HER-2/neu expression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

High p27Kip1 Expression Predicts Superior Relapse-Free and Overall Survival for Premenopausal Women With Early-Stage Breast Cancer Receiving Adjuvant Treatment With Tamoxifen Plus Goserelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The 3'-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

p(21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Role of proliferation in HER2 status predicted response to doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

The relationship between prognostic and predictive factors in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352

p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI352